CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

Quantum Genomics Raises €3 Million in Non-dilutive Financing

Life Sciences Review Life Sciences Review | Wednesday, August 18, 2021
Tweet

The latest funding secured by Quantum Genomics will enable the acceleration of R&D programs.


FREMONT, CA: Quantum Genomics, a biopharmaceutical firm specializing in the development of a new class of drugs that directly targets the brain to treat difficult-to-treat/resistant hypertension and heart failure, today announces it has secured ‚ €3 million in non-dilutive financing through grants from the French government and BNP bank and an R&D loan from Bpifrance.


BNP bank has given a ‚ €1.5 million loan, guaranteed by the French government (PGE) with an initial 12 months maturity, at a rate of 0.25 percent. The firm has been offered the option to request five years amortization. Bpifrance has granted a ‚ €1.5 million innovation and R&D loan for 7.6 years at an interest rate of 0.72 percent. The first reimbursement is scheduled for December 31, 2023.


 


The Company would like to thank the French government, Bpifrance, and its banking partners for supporting this financing. This additional non-dilutive financing, which processes were initiated last November 2020, secured the treasury in a context that remains uncertain. This comes at an essential time for the Company, following the recent capital raise in December 2020 and the signing of several partnerships with different strategic partners in 2020, all of which will strengthen and boost R&D programs.


Quantum Genomics is a biopharmaceutical firm specializing in developing a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only firm in the world exploring this innovative method that directly targets the brain.


Weekly Brief

loading
Top 10 Genomics Solutions Companies in Europe/UK – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/quantum-genomics-raises-3-million-in-nondilutive-financing-nwid-368.html